Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Cancer cells exhibit enhanced aerobic glycolysis, a metabolic vulnerability.
• Previous attempts to inhibit glycolysis for cancer treatment were limited by systemic toxicity.
• Combined inhibition of glycolysis and mitochondrial function is a potential strategy to overcome toxicity.

Purpose of the Study:

• To investigate the chemotherapeutic efficacy of mitochondria-targeted drugs (MTDs) combined with 2-deoxy-d-glucose (2-DG).
• To evaluate the synergistic effects of MTDs and 2-DG on cancer cell ATP levels, bioenergetic function, and survival.
• To assess the in vivo efficacy and toxicity of the combined treatment in a human breast cancer xenograft model.

Main Methods:

• Utilized mitochondria-targeted drugs (Mito-CP, Mito-Q) and 2-deoxy-d-glucose (2-DG).
• Assessed cytotoxic effects and mitochondrial bioenergetic changes in vitro.
• Evaluated tumor regression and organ morphology in a human breast cancer xenograft model.

Main Results:

• Mito-CP and Mito-Q synergized with 2-DG to decrease ATP levels in cancer cell lines.
• Cellular bioenergetic function and survival were partially restored over time in some cell lines.
• Combined Mito-CP and 2-DG treatment significantly reduced tumor size in vivo with no observed kidney, liver, or heart toxicity.

Conclusions:

• Dual targeting of cancer cell metabolism by inhibiting both mitochondrial function and glycolysis is a viable therapeutic strategy.
• Mitochondria-targeted drugs combined with glycolytic inhibitors like 2-DG demonstrate significant anti-tumor efficacy.
• This combination therapy offers a promising approach for cancer treatment with reduced systemic toxicity.